US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enliven Treateutics

21.70

-0.3700-1.68%

Volume:671.04K

Turnover:14.61M

Market Cap:1.29B

PE:-10.84

High:22.27

Open:21.77

Low:21.28

Close:22.07

52wk High:26.48

52wk Low:13.30

Shares:59.35M

Float Shares:35.00M

Volume Ratio:1.37

T/O Rate:1.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0009

EPS(LYR):-1.8912

ROE:-25.43%

ROA:-17.62%

PB:2.70

PE(LYR):-11.47

Loading ...

Overview Company News Filings

Enliven Therapeutics COO Anish Patel Reports Sale of Common Shares

Enliven Therapeutics reports third quarter net loss of $20.1 million

Enliven Therapeutics: Remains on Track to Initiate Phase 3 Pivotal Trial of Elvn-001 in 2026

THOMSON REUTERS

Mizuho Securities Remains a Buy on Enliven Therapeutics (ELVN)

Enliven Therapeutics Down Nearly 18%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk

Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment

Enliven Therapeutics Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts

Enliven Therapeutics Announces Clinical Data in Cml Patients With Atypical Fusion Transcripts at Ash 2025 Annual Meeting

THOMSON REUTERS

Enliven Therapeutics (ELVN): Evaluating Valuation Following Phase 1 ELVN-001 Update for Resistant Leukemia

Simply Wall St.

Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares

Enliven Therapeutics CEO Samuel Kintz Reports Sale of Common Shares

JonesTrading Sticks to Its Buy Rating for Enliven Therapeutics (ELVN)

Enliven Therapeutics (ELVN): Evaluating Valuation After Recent Share Price Momentum

Simply Wall St.

Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares in Enliven Therapeutics Inc

Samuel Kintz, President and CEO, Reports Disposal of Enliven Therapeutics Common Shares

Enliven Therapeutics Inc.'s COO Anish Patel Reports Disposal of Common Shares

CFO Benjamin Hohl Reports Disposal of Common Shares in Enliven Therapeutics Inc

BRIEF-Enliven Therapeutics Announces Oral And Poster Presentations At The Society Of Hematologic Oncology (Soho) 2025 Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ELVN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELVN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":21.7,"timestamp":1763412543216,"preClose":22.07,"halted":0,"volume":671042,"delay":0,"floatShares":34999600,"shares":59347317,"eps":-2.000926,"marketStatus":"Trading","change":-0.37,"latestTime":"11-17 15:49:04 EST","open":21.77,"high":22.27,"low":21.28,"amount":14607238.229748001,"amplitude":0.044857,"askPrice":21.7,"askSize":555,"bidPrice":21.66,"bidSize":219,"shortable":3,"etf":0,"ttmEps":-2.000926,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":22.07,"preHourTrading":{"tag":"盘前","latestPrice":22.2,"preClose":22.07,"latestTime":"09:17 EST","volume":1085,"amount":24233.2797,"timestamp":1763389039968},"postHourTrading":{"tag":"盘后","latestPrice":22.07,"preClose":22.07,"latestTime":"17:34 EST","volume":13322,"amount":294016.54,"timestamp":1763159679567},"volumeRatio":1.371117,"impliedVol":0.5158,"impliedVolPercentile":0.38},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","floatShares":34999600,"roa":"-17.62%","roe":"-25.43%","lyrEps":-1.891209,"volumeRatio":1.371117,"shares":59347317,"dividePrice":0,"high":22.27,"amplitude":0.044857,"preClose":22.07,"low":21.28,"week52Low":13.3,"pbRate":"2.70","week52High":26.48,"institutionHeld":0,"latestPrice":21.7,"committee":-0.434109,"eps":-2.000926,"divideRate":0,"volume":671042,"delay":0,"ttmEps":-2.000926,"open":21.77,"prevYearClose":22.5,"prevWeekClose":22.07,"prevMonthClose":23.42,"prevQuarterClose":20.47,"fiveDayClose":18.71,"twentyDayClose":22.12,"sixtyDayClose":20.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELVN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ELVN","fiscalQuarterEnding":"2025/09","expectedEps":-0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-13","symbol":"ELVN","fiscalQuarterEnding":"2025/06","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-14","symbol":"ELVN","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.57},{"market":"US","date":"2025-03-13","symbol":"ELVN","fiscalQuarterEnding":"2024/12","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2024-11-13","symbol":"ELVN","fiscalQuarterEnding":"2024/09","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELVN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELVN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1755320400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELVN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELVN","date":"2025-11-14","current":-10.837482,"percent":0.596358,"low":-26.682642,"twenty":-15.986677,"median":-12.54534,"eighty":-10.635951,"high":-6.665619,"avg":-13.450621,"sd":4.054733,"marketCap":1202970115},"quantilePoints":[{"date":"2023-02-24","current":-26.682642,"twenty":-26.682642,"median":-26.682642,"eighty":-26.682642,"marketCap":974023148},{"date":"2023-03-03","current":-24.8289,"twenty":-26.345598,"median":-24.559265,"eighty":-24.199752,"marketCap":906354172},{"date":"2023-03-10","current":-23.694186,"twenty":-25.199648,"median":-24.28963,"eighty":-23.806534,"marketCap":864932556},{"date":"2023-03-17","current":-24.997422,"twenty":-25.053596,"median":-24.508708,"eighty":-23.817768,"marketCap":912505897},{"date":"2023-03-24","current":-25.045524,"twenty":-25.045524,"median":-24.501056,"eighty":-23.817768,"marketCap":943264523},{"date":"2023-03-31","current":-23.847695,"twenty":-25.154418,"median":-24.513309,"eighty":-23.847695,"marketCap":898151871},{"date":"2023-04-06","current":-25.11086,"twenty":-25.119572,"median":-24.513309,"eighty":-23.847695,"marketCap":945725213},{"date":"2023-04-14","current":-20.962015,"twenty":-25.076502,"median":-24.390743,"eighty":-23.811629,"marketCap":789471394},{"date":"2023-04-21","current":-21.332253,"twenty":-25.048753,"median":-24.119928,"eighty":-22.848051,"marketCap":803415304},{"date":"2023-04-28","current":-20.635334,"twenty":-25.016663,"median":-23.926845,"eighty":-21.458569,"marketCap":777167943},{"date":"2023-05-05","current":-20.341321,"twenty":-24.896309,"median":-23.847695,"eighty":-21.260383,"marketCap":766094838},{"date":"2023-05-12","current":-20.851059,"twenty":-24.795534,"median":-23.81078,"eighty":-20.994683,"marketCap":785292584},{"date":"2023-05-19","current":-21.89907,"twenty":-24.705543,"median":-23.593073,"eighty":-21.113722,"marketCap":824762787},{"date":"2023-05-26","current":-21.462399,"twenty":-24.613192,"median":-22.720646,"eighty":-21.211975,"marketCap":808316869},{"date":"2023-06-02","current":-18.734285,"twenty":-24.559265,"median":-21.980633,"eighty":-20.954392,"marketCap":819006716},{"date":"2023-06-09","current":-21.377022,"twenty":-24.515759,"median":-21.83357,"eighty":-20.954392,"marketCap":934539290},{"date":"2023-06-16","current":-18.254642,"twenty":-24.497376,"median":-21.673899,"eighty":-20.758384,"marketCap":798038170},{"date":"2023-06-23","current":-20.812737,"twenty":-24.451411,"median":-21.642525,"eighty":-20.734427,"marketCap":909870413},{"date":"2023-06-30","current":-18.32988,"twenty":-24.28963,"median":-21.616844,"eighty":-20.341321,"marketCap":801327354},{"date":"2023-07-07","current":-17.361189,"twenty":-24.217728,"median":-21.517191,"eighty":-20.09872,"marketCap":758979115},{"date":"2023-07-14","current":-17.135475,"twenty":-24.135893,"median":-21.462399,"eighty":-19.332427,"marketCap":749111564},{"date":"2023-07-21","current":-17.972499,"twenty":-24.119928,"median":-21.435107,"eighty":-18.517975,"marketCap":785703732},{"date":"2023-07-28","current":-16.984999,"twenty":-23.971833,"median":-21.377022,"eighty":-18.220785,"marketCap":742533197},{"date":"2023-08-04","current":-16.881547,"twenty":-23.922067,"median":-21.256028,"eighty":-17.820142,"marketCap":738010570},{"date":"2023-08-11","current":-16.491696,"twenty":-23.861932,"median":-21.016461,"eighty":-17.568094,"marketCap":720967464},{"date":"2023-08-18","current":-12.980214,"twenty":-23.847695,"median":-20.922018,"eighty":-17.248332,"marketCap":669117064},{"date":"2023-08-25","current":-13.578933,"twenty":-23.823753,"median":-20.812737,"eighty":-17.129832,"marketCap":699980398},{"date":"2023-09-01","current":-12.469308,"twenty":-23.815574,"median":-20.736061,"eighty":-17.000046,"marketCap":642780353},{"date":"2023-09-08","current":-12.908368,"twenty":-23.809931,"median":-20.564155,"eighty":-16.862737,"marketCap":665413464},{"date":"2023-09-15","current":-13.123907,"twenty":-23.739125,"median":-20.333094,"eighty":-16.776213,"marketCap":676524264},{"date":"2023-09-22","current":-10.154264,"twenty":-23.633518,"median":-19.996164,"eighty":-15.495828,"marketCap":523442131},{"date":"2023-09-29","current":-10.968521,"twenty":-23.474031,"median":-19.373808,"eighty":-13.527842,"marketCap":565416265},{"date":"2023-10-06","current":-11.511359,"twenty":-23.372472,"median":-19.044642,"eighty":-13.224491,"marketCap":593399020},{"date":"2023-10-13","current":-9.994605,"twenty":-22.593241,"median":-18.52738,"eighty":-13.107941,"marketCap":515211909},{"date":"2023-10-20","current":-10.130315,"twenty":-22.058041,"median":-18.391011,"eighty":-12.999373,"marketCap":522207598},{"date":"2023-10-27","current":-9.555545,"twenty":-22.040989,"median":-18.292261,"eighty":-12.964248,"marketCap":492578798},{"date":"2023-11-03","current":-9.731169,"twenty":-21.920278,"median":-17.972499,"eighty":-12.485274,"marketCap":501632043},{"date":"2023-11-10","current":-7.695346,"twenty":-21.89907,"median":-17.817321,"eighty":-12.245786,"marketCap":475295332},{"date":"2023-11-17","current":-6.952736,"twenty":-21.83357,"median":-17.803213,"eighty":-11.215991,"marketCap":429428758},{"date":"2023-11-24","current":-7.786797,"twenty":-21.720035,"median":-17.492856,"eighty":-10.958941,"marketCap":480943724},{"date":"2023-12-01","current":-7.513225,"twenty":-21.68071,"median":-17.309463,"eighty":-10.760965,"marketCap":464046815},{"date":"2023-12-08","current":-7.506552,"twenty":-21.671453,"median":-17.210713,"eighty":-10.505512,"marketCap":463634696},{"date":"2023-12-15","current":-7.893557,"twenty":-21.652352,"median":-17.121368,"eighty":-10.333081,"marketCap":487537640},{"date":"2023-12-22","current":-8.620858,"twenty":-21.63925,"median":-17.013213,"eighty":-10.031327,"marketCap":532458691},{"date":"2023-12-29","current":-9.721819,"twenty":-21.630859,"median":-16.994403,"eighty":-9.985025,"marketCap":600458446},{"date":"2024-01-05","current":-9.735164,"twenty":-21.621546,"median":-16.919166,"eighty":-9.908649,"marketCap":601282686},{"date":"2024-01-12","current":-7.653347,"twenty":-21.612141,"median":-16.825118,"eighty":-9.735164,"marketCap":472701330},{"date":"2024-01-19","current":-8.547461,"twenty":-21.544748,"median":-16.787499,"eighty":-9.657763,"marketCap":527925374},{"date":"2024-01-26","current":-10.90285,"twenty":-21.510766,"median":-16.702856,"eighty":-9.657763,"marketCap":673403638},{"date":"2024-02-02","current":-10.972911,"twenty":-21.471637,"median":-15.246862,"eighty":-9.711143,"marketCap":677730895},{"date":"2024-02-09","current":-10.282309,"twenty":-21.462504,"median":-13.618847,"eighty":-9.729299,"marketCap":635076503},{"date":"2024-02-16","current":-11.543409,"twenty":-21.454109,"median":-13.399317,"eighty":-9.734365,"marketCap":712967132},{"date":"2024-02-23","current":-10.609261,"twenty":-21.445153,"median":-13.291548,"eighty":-9.761506,"marketCap":655270370},{"date":"2024-03-01","current":-10.655968,"twenty":-21.434015,"median":-13.147855,"eighty":-9.803015,"marketCap":658155208},{"date":"2024-03-08","current":-10.275636,"twenty":-21.409359,"median":-13.10395,"eighty":-9.82474,"marketCap":634664384},{"date":"2024-03-15","current":-6.665619,"twenty":-21.384546,"median":-13.044078,"eighty":-9.733566,"marketCap":477151673},{"date":"2024-03-22","current":-10.431636,"twenty":-21.350161,"median":-12.972231,"eighty":-9.727429,"marketCap":746738233},{"date":"2024-03-28","current":-10.760874,"twenty":-21.310474,"median":-12.880428,"eighty":-9.732767,"marketCap":770306384},{"date":"2024-04-05","current":-12.135517,"twenty":-21.260383,"median":-12.485274,"eighty":-9.752725,"marketCap":868708833},{"date":"2024-04-12","current":-15.541291,"twenty":-21.211975,"median":-12.53879,"eighty":-9.795033,"marketCap":1112507764},{"date":"2024-04-19","current":-11.553574,"twenty":-21.113722,"median":-12.520461,"eighty":-9.82282,"marketCap":827051011},{"date":"2024-04-26","current":-10.971645,"twenty":-20.994683,"median":-12.453342,"eighty":-9.833917,"marketCap":785394226},{"date":"2024-05-03","current":-13.724364,"twenty":-20.956933,"median":-12.42141,"eighty":-9.861485,"marketCap":982444863},{"date":"2024-05-10","current":-15.627075,"twenty":-20.927476,"median":-12.477291,"eighty":-9.897956,"marketCap":1118648510},{"date":"2024-05-17","current":-14.069999,"twenty":-20.877259,"median":-12.55712,"eighty":-9.908649,"marketCap":1119943779},{"date":"2024-05-24","current":-13.579529,"twenty":-20.83573,"median":-12.880428,"eighty":-9.913987,"marketCap":1080903320},{"date":"2024-05-31","current":-13.31952,"twenty":-20.807747,"median":-12.919935,"eighty":-9.925997,"marketCap":1060207172},{"date":"2024-06-07","current":-11.936748,"twenty":-20.777985,"median":-12.852488,"eighty":-9.949337,"marketCap":950141299},{"date":"2024-06-14","current":-13.012238,"twenty":-20.738783,"median":-12.908368,"eighty":-9.978639,"marketCap":1035748089},{"date":"2024-06-21","current":-12.433128,"twenty":-20.734427,"median":-12.823141,"eighty":-9.991412,"marketCap":989652125},{"date":"2024-06-28","current":-13.857265,"twenty":-20.713737,"median":-12.852488,"eighty":-9.999395,"marketCap":1103010568},{"date":"2024-07-05","current":-12.734501,"twenty":-20.635334,"median":-12.852488,"eighty":-10.018554,"marketCap":1013640841},{"date":"2024-07-12","current":-14.217731,"twenty":-20.492975,"median":-12.947875,"eighty":-10.03452,"marketCap":1131702953},{"date":"2024-07-15","current":-14.619562,"twenty":-20.462644,"median":-12.964248,"eighty":-10.034701,"marketCap":1163687908},{"date":"2024-08-02","current":-14.595925,"twenty":-20.432313,"median":-12.972231,"eighty":-10.034882,"marketCap":1161806440},{"date":"2024-08-09","current":-12.834959,"twenty":-20.33803,"median":-12.964248,"eighty":-10.054109,"marketCap":1021637080},{"date":"2024-08-16","current":-13.556309,"twenty":-20.306761,"median":-12.945278,"eighty":-10.088634,"marketCap":1122828410},{"date":"2024-08-23","current":-13.060138,"twenty":-20.227193,"median":-12.964248,"eighty":-10.111156,"marketCap":1081732040},{"date":"2024-08-30","current":-12.672326,"twenty":-20.030349,"median":-12.961651,"eighty":-10.130701,"marketCap":1049610739},{"date":"2024-09-06","current":-12.495529,"twenty":-19.786892,"median":-12.919935,"eighty":-10.135876,"marketCap":1034967205},{"date":"2024-09-13","current":-12.73506,"twenty":-19.581572,"median":-12.931502,"eighty":-10.154517,"marketCap":1054806832},{"date":"2024-09-20","current":-13.157091,"twenty":-19.368165,"median":-12.8873,"eighty":-10.156457,"marketCap":1089762365},{"date":"2024-09-27","current":-13.755918,"twenty":-19.332427,"median":-12.959054,"eighty":-10.16247,"marketCap":1139361432},{"date":"2024-10-04","current":-14.548651,"twenty":-19.185713,"median":-12.995005,"eighty":-10.191351,"marketCap":1205021150},{"date":"2024-10-11","current":-15.381306,"twenty":-18.794475,"median":-13.012238,"eighty":-10.271051,"marketCap":1273987472},{"date":"2024-10-18","current":-15.980134,"twenty":-18.692904,"median":-13.06278,"eighty":-10.276971,"marketCap":1323586540},{"date":"2024-10-25","current":-16.527633,"twenty":-18.517975,"median":-13.077247,"eighty":-10.282309,"marketCap":1368934258},{"date":"2024-10-31","current":-16.191149,"twenty":-18.480356,"median":-13.117169,"eighty":-10.282309,"marketCap":1341064306},{"date":"2024-11-08","current":-16.539039,"twenty":-18.452142,"median":-13.127899,"eighty":-10.308998,"marketCap":1369879003},{"date":"2024-11-15","current":-14.288385,"twenty":-18.32988,"median":-13.147855,"eighty":-10.377785,"marketCap":1217570416},{"date":"2024-11-22","current":-14.569336,"twenty":-18.254642,"median":-13.191309,"eighty":-10.377785,"marketCap":1241511408},{"date":"2024-11-29","current":-13.978765,"twenty":-18.119213,"median":-13.257473,"eighty":-10.420866,"marketCap":1191186467},{"date":"2024-12-06","current":-13.330857,"twenty":-17.99507,"median":-13.275582,"eighty":-10.465191,"marketCap":1135975609},{"date":"2024-12-13","current":-13.187514,"twenty":-17.927356,"median":-13.313517,"eighty":-10.47358,"marketCap":1123760818},{"date":"2024-12-20","current":-13.112976,"twenty":-17.840832,"median":-13.307514,"eighty":-10.475365,"marketCap":1117409126},{"date":"2024-12-27","current":-13.021237,"twenty":-17.81638,"median":-13.27352,"eighty":-10.487821,"marketCap":1109591659},{"date":"2025-01-03","current":-13.703547,"twenty":-17.808856,"median":-13.27352,"eighty":-10.502895,"marketCap":1167734067},{"date":"2025-01-10","current":-13.84689,"twenty":-17.803213,"median":-13.275582,"eighty":-10.521478,"marketCap":1179948858},{"date":"2025-01-17","current":-12.60841,"twenty":-17.759951,"median":-13.27352,"eighty":-10.564579,"marketCap":1074413060},{"date":"2025-01-24","current":-12.637079,"twenty":-17.586904,"median":-13.268745,"eighty":-10.609261,"marketCap":1076856018},{"date":"2025-01-31","current":-12.195584,"twenty":-17.492856,"median":-13.225528,"eighty":-10.642623,"marketCap":1039234460},{"date":"2025-02-07","current":-12.883628,"twenty":-17.445832,"median":-13.157091,"eighty":-10.649204,"marketCap":1097865460},{"date":"2025-02-14","current":-12.327459,"twenty":-17.361189,"median":-13.147855,"eighty":-10.655968,"marketCap":1050472069},{"date":"2025-02-21","current":-12.310258,"twenty":-17.278427,"median":-13.123907,"eighty":-10.661306,"marketCap":1049006294},{"date":"2025-02-28","current":-11.553409,"twenty":-17.220118,"median":-13.115073,"eighty":-10.671914,"marketCap":984512194},{"date":"2025-03-07","current":-12.304524,"twenty":-17.210713,"median":-13.077247,"eighty":-10.692528,"marketCap":1048517702},{"date":"2025-03-14","current":-11.168896,"twenty":-17.203189,"median":-13.06278,"eighty":-10.70156,"marketCap":994299783},{"date":"2025-03-21","current":-11.515688,"twenty":-17.148642,"median":-13.044078,"eighty":-10.73075,"marketCap":1025172571},{"date":"2025-03-28","current":-11.840461,"twenty":-17.112904,"median":-13.012192,"eighty":-10.756253,"marketCap":1054085181},{"date":"2025-04-04","current":-11.025775,"twenty":-17.062118,"median":-12.992568,"eighty":-10.756253,"marketCap":981558632},{"date":"2025-04-11","current":-8.207404,"twenty":-17.020737,"median":-12.961651,"eighty":-10.671914,"marketCap":730655976},{"date":"2025-04-17","current":-8.845942,"twenty":-17.00757,"median":-12.919935,"eighty":-10.646572,"marketCap":787501109},{"date":"2025-04-25","current":-10.073474,"twenty":-16.992523,"median":-12.900829,"eighty":-10.506428,"marketCap":896780977},{"date":"2025-05-02","current":-10.926692,"twenty":-16.945499,"median":-12.87493,"eighty":-10.47358,"marketCap":972737836},{"date":"2025-05-09","current":-10.268015,"twenty":-16.896595,"median":-12.837758,"eighty":-10.456802,"marketCap":914099729},{"date":"2025-05-16","current":-9.22086,"twenty":-16.864245,"median":-12.824716,"eighty":-10.419165,"marketCap":874414177},{"date":"2025-05-23","current":-8.677544,"twenty":-16.841798,"median":-12.774982,"eighty":-10.35027,"marketCap":822891456},{"date":"2025-05-30","current":-9.179465,"twenty":-16.826999,"median":-12.740411,"eighty":-10.284647,"marketCap":870488636},{"date":"2025-06-06","current":-11.057788,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"marketCap":1048610043},{"date":"2025-06-13","current":-10.172958,"twenty":-16.787499,"median":-12.717951,"eighty":-10.278305,"marketCap":964701612},{"date":"2025-06-20","current":-13.417901,"twenty":-16.781856,"median":-12.734501,"eighty":-10.282309,"marketCap":1272419584},{"date":"2025-06-27","current":-13.386798,"twenty":-16.747999,"median":-12.73478,"eighty":-10.283478,"marketCap":1269470072},{"date":"2025-07-03","current":-12.895368,"twenty":-16.702856,"median":-12.73478,"eighty":-10.288155,"marketCap":1222867778},{"date":"2025-07-11","current":-14.170598,"twenty":-16.684047,"median":-12.73506,"eighty":-10.29197,"marketCap":1343797781},{"date":"2025-07-18","current":-14.518953,"twenty":-16.539039,"median":-12.769279,"eighty":-10.308998,"marketCap":1376832318},{"date":"2025-07-25","current":-13.654285,"twenty":-16.539039,"median":-12.823141,"eighty":-10.377785,"marketCap":1294835877},{"date":"2025-08-01","current":-11.701007,"twenty":-16.527633,"median":-12.814277,"eighty":-10.377785,"marketCap":1109606508},{"date":"2025-08-08","current":-11.13493,"twenty":-16.527633,"median":-12.763576,"eighty":-10.392743,"marketCap":1055925385},{"date":"2025-08-15","current":-11.683894,"twenty":-16.52193,"median":-12.73478,"eighty":-10.409257,"marketCap":1170901400},{"date":"2025-08-22","current":-11.727119,"twenty":-16.516227,"median":-12.729357,"eighty":-10.425771,"marketCap":1175233252},{"date":"2025-08-29","current":-12.034483,"twenty":-16.491696,"median":-12.666623,"eighty":-10.431636,"marketCap":1206035736},{"date":"2025-09-05","current":-11.827604,"twenty":-16.470258,"median":-12.655877,"eighty":-10.465191,"marketCap":1185303295},{"date":"2025-09-12","current":-11.774406,"twenty":-16.437524,"median":-12.642812,"eighty":-10.47358,"marketCap":1179972096},{"date":"2025-09-19","current":-11.777361,"twenty":-16.362242,"median":-12.617902,"eighty":-10.475365,"marketCap":1180268273},{"date":"2025-09-26","current":-10.976442,"twenty":-16.281259,"median":-12.614144,"eighty":-10.477125,"marketCap":1100004107},{"date":"2025-10-03","current":-11.774406,"twenty":-16.205977,"median":-12.604497,"eighty":-10.492153,"marketCap":1179972096},{"date":"2025-10-10","current":-12.584192,"twenty":-16.158355,"median":-12.584192,"eighty":-10.509962,"marketCap":1261124795},{"date":"2025-10-17","current":-12.856091,"twenty":-16.100826,"median":-12.570656,"eighty":-10.522555,"marketCap":1288373147},{"date":"2025-10-24","current":-12.146789,"twenty":-16.047431,"median":-12.55712,"eighty":-10.547691,"marketCap":1217290490},{"date":"2025-10-31","current":-14.168299,"twenty":-16.017711,"median":-12.59139,"eighty":-10.598091,"marketCap":1419876061},{"date":"2025-11-07","current":-10.816849,"twenty":-16.012848,"median":-12.55712,"eighty":-10.635951,"marketCap":1084010510},{"date":"2025-11-14","current":-12.003893,"twenty":-15.986677,"median":-12.54534,"eighty":-10.635951,"marketCap":1202970115}],"updateTime":1763403599764},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELVN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583221589","title":"Enliven Therapeutics COO Anish Patel Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583221589","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583221589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:34","pubTimestamp":1762986882,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL336f6Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics COO Anish Patel Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2583588147","title":"Enliven Therapeutics reports third quarter net loss of $20.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588147?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:08","pubTimestamp":1762981682,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. reported a net loss of $20.1 million for the third quarter of 2025, compared to a net loss of $23.2 million in the same period of 2024. Research and development expenses were $18.2 million, down from $21.3 million in the prior year's quarter. General and administrative expenses totaled $6.9 million, up from $5.8 million in the third quarter of 2024. As of September 30, 2025, the company held $477.6 million in cash, cash equivalents, and marketable securities, expected to provide a cash runway into the first half of 2029. During the quarter, Enliven completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial of ELVN-001 in CML and remains on track to initiate a Phase 3 pivotal trial in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6Vfsn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2583588766","title":"Enliven Therapeutics: Remains on Track to Initiate Phase 3 Pivotal Trial of Elvn-001 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583588766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583588766?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXF51E2A:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2580223154","title":"Mizuho Securities Remains a Buy on Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580223154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580223154?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:05","pubTimestamp":1762203923,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed maintained a Buy rating on Enliven Therapeutics today and set a price target of $41.00. The company’s shares c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ELVN","BK4539","LENZ","BK4207","BK4007","MFG"],"gpt_icon":0},{"id":"2580242862","title":"Enliven Therapeutics Down Nearly 18%, on Pace for Largest Percent Decrease Since April 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2580242862","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580242862?lang=en_us&edition=fundamental","pubTime":"2025-11-04 03:36","pubTimestamp":1762198560,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc.  is currently at $19.27, down $4.15 or 17.72%. --Would be lowest close since Sept. 25, 2025, when it closed at $18.57. --On pace for largest percent decrease since April 5, 2022, when it fell 22.09%. --Currently down two consecutive days; down 19.61% over this period. --Down 14.36% year-to-date; on pace for worst year since 2023, when it fell 15.4%. --Down 91.22% from its all-time closing high of $219.48 on June 11, 2020. --Down 30.31% from 52 weeks ago , when it closed at $27.65. --Up 29.24% from its 52-week closing low of $14.91 on April 10, 2025. --Traded as low as $18.33; lowest intraday level since Sept. 26, 2025, when it hit $18.28. --Down 21.73% at today's intraday low; largest intraday percent decrease since April 5, 2022, when it fell as much as 37.42%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","ELVN","BK4007"],"gpt_icon":0},{"id":"2580776241","title":"Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2580776241","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580776241?lang=en_us&edition=fundamental","pubTime":"2025-11-04 02:45","pubTimestamp":1762195515,"startTime":"0","endTime":"0","summary":"Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and keeping the price target at $38.00. Sam Slutsky has gi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-investment-opportunity-enliven-therapeutics-elvn-001-shows-strong-potential-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-investment-opportunity-enliven-therapeutics-elvn-001-shows-strong-potential-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","ELVN","BK4007"],"gpt_icon":0},{"id":"2580196752","title":"Enliven Therapeutics Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts","url":"https://stock-news.laohu8.com/highlight/detail?id=2580196752","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580196752?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:06","pubTimestamp":1762178771,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. announced that it will present preliminary clinical data from the ongoing ENABLE Phase 1a/1b trial of ELVN-001, a selective active site inhibitor of BCR::ABL1, in chronic myeloid leukemia  patients with atypical fusion transcripts at the 67th Annual American Society of Hematology  2025 Annual Meeting. The presentation is scheduled for December 7, 2025, in Orlando, Florida. According to the company, ELVN-001 demonstrated encouraging anti-CML activity in a heavily pretreated patient population, including those with the e13a3 fusion transcript, which is resistant to certain tyrosine kinase inhibitors. Detailed data will be available following the presentation on Enliven Therapeutics' website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5GNPqb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2580219625","title":"Enliven Therapeutics Announces Clinical Data in Cml Patients With Atypical Fusion Transcripts at Ash 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219625?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:05","pubTimestamp":1762178753,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA4F60GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2578070938","title":"Enliven Therapeutics (ELVN): Evaluating Valuation Following Phase 1 ELVN-001 Update for Resistant Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2578070938","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578070938?lang=en_us&edition=fundamental","pubTime":"2025-10-28 13:22","pubTimestamp":1761628954,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) recently caught investors’ attention with updates on its Phase 1 studies for ELVN-001, an experimental treatment targeting chronic myeloid leukemia patients who are resistant or intolerant to existing therapies, including those with the T315I mutation.\nSee our latest analysis for Enliven Therapeutics.\nEnliven Therapeutics’ latest trial updates have sparked new interest, and while momentum has been mixed, the stock’s 6.95% 1-month share price return hints at revived...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-evaluating-valuation-following-pha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-evaluating-valuation-following-pha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LENZ","BK4007","ELVN","BK4539"],"gpt_icon":0},{"id":"2577622343","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577622343","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577622343?lang=en_us&edition=fundamental","pubTime":"2025-10-23 07:21","pubTimestamp":1761175295,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL3gnHq1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2577383380","title":"Enliven Therapeutics CEO Samuel Kintz Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2577383380","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577383380?lang=en_us&edition=fundamental","pubTime":"2025-10-22 06:14","pubTimestamp":1761084843,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL2vtnWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2576377190","title":"JonesTrading Sticks to Its Buy Rating for Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576377190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576377190?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:17","pubTimestamp":1760703460,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Soumit Roy from JonesTrading maintained a Buy rating on Enliven Therapeutics. The company’s shares closed yesterday...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2574466624","title":"Enliven Therapeutics (ELVN): Evaluating Valuation After Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2574466624","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574466624?lang=en_us&edition=fundamental","pubTime":"2025-10-12 02:15","pubTimestamp":1760206531,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) shares have been active lately, reflecting a recent swing in investor sentiment. Over the past week, the stock moved up about 6%, reversing some decline from the past 3 months.\nSee our latest analysis for Enliven Therapeutics.\nAfter a challenging stretch, Enliven Therapeutics is showing some renewed momentum. A 1-month share price return of 8% is helping counter its 12.9% year-to-date decline. Despite these recent gains, its 1-year total shareholder return remains...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-evaluating-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-evaluating-valuation-after-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","LENZ","ELVN","BK4539"],"gpt_icon":0},{"id":"2574926031","title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574926031","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574926031?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:21","pubTimestamp":1760044908,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDLbvWL2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2572377129","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2572377129","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572377129?lang=en_us&edition=fundamental","pubTime":"2025-10-01 05:52","pubTimestamp":1759269143,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., has reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL7LNHsn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2569749316","title":"Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares in Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2569749316","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569749316?lang=en_us&edition=fundamental","pubTime":"2025-09-24 05:15","pubTimestamp":1758662103,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL12vhFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2569710656","title":"Samuel Kintz, President and CEO, Reports Disposal of Enliven Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2569710656","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569710656?lang=en_us&edition=fundamental","pubTime":"2025-09-24 01:57","pubTimestamp":1758650256,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL8JLVYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2566193574","title":"Enliven Therapeutics Inc.'s COO Anish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2566193574","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566193574?lang=en_us&edition=fundamental","pubTime":"2025-09-11 08:13","pubTimestamp":1757549591,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL2dZPvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2563726010","title":"CFO Benjamin Hohl Reports Disposal of Common Shares in Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2563726010","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563726010?lang=en_us&edition=fundamental","pubTime":"2025-08-30 05:03","pubTimestamp":1756501431,"startTime":"0","endTime":"0","summary":"Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL9llWbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2562427552","title":"BRIEF-Enliven Therapeutics Announces Oral And Poster Presentations At The Society Of Hematologic Oncology (Soho) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2562427552","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562427552?lang=en_us&edition=fundamental","pubTime":"2025-08-26 06:23","pubTimestamp":1756160584,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Announces Oral And Poster Presentations At The Society Of Hematologic Oncology (Soho) 2025 Annual MeetingAug 25 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUAPBSZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}